Based on this, it can be concluded that effective response to immune checkpoint therapy in advanced and metastatic ccRCC requires an absolute or relative absence of dysfunctional M2-like TAMs and exhausted CD8+ T cells, or the presence of progenitor exhausted CD8+ T cells. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.